Amply™ Technology has demonstrated up to 10x productivity and stability improvement on mouse, sheep and human hybridomas for IVD applications.
Hybridomas are immortalized cells issued from the fusion of short-lived B cell which secretes antibodies of one specificity with a long-lived myeloma cell, a technique developed in 1975 by Kohler and Milstein, awarded with Nobel Prize. Antibodies produced by hybridoma expression system are all of a single specificity and are therefore monoclonal antibodies.
Since this period, hybridoma cell lines have allowed the production of monoclonal antibodies for diagnostic purpose but also with therapeutic ambition. OKT3 (Ortho Biotech) was the first murine monoclonal antibody produced for the treatment of acute transplant rejection. It has been followed by several monoclonal antibodies blockbusters, also produced in hybridoma expression system, such as Remicade (infliximab), Synagis (palivizumab), Soliris (eculizumab), Tysabri (natalizumab) and Stelara (ustekinumab).
But antibody production by hybridoma cell lines remains unstable. Failure to maintain cell lines properly leads to loss in antibody productivity and eventually the clone itself. Some other problems generally appear including the degenerecence of reduction of monoclonality over the time.
The following example represents an optimization of a hybridoma cell line for ImmunoDiagnostic Systems (IDS SA).
The original hybridoma cell line is represented in red.
After the application of Amply™ Technology, the high-titer hybridoma – represented in green – showed a 5.6 times higher productivity.
The cells’s production period has increased by 5 months.
The mass of antibodies recovered in the same bioreactor is 20x higher.